Fosamax Osteonecrosis of the Jaw Attorney: California Fosamax Osteonecrosis of the Jaw Injury Lawyer

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Awareness

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatment options. Within this broad domain, the dissemination of knowledge about prescription medications and their potential side effects has been a critical component, enabling patients and healthcare providers to make informed decisions. This heritage of accessible, evidence-based communication has historically focused on therapeutic benefits and general risk awareness, often framed within a population-level context. As this informational framework evolves, a natural pivot occurs toward more specific, real-world applications of health science. The transition from broad educational content to targeted occupational and environmental health concerns becomes necessary when considering the pathways through which individuals encounter pharmaceutical agents. In particular, the shift from general awareness of medication risks to a focused examination of exposure scenarios is essential for understanding how certain patient populations may face heightened vulnerabilities. This pivot does not require mechanistic detail but rather acknowledges that the context of exposure—whether through prescribed use or other means—shapes the risk profile. By moving from the general to the specific, the informational legacy now accommodates a nuanced exploration of how pharmaceutical exposure, such as that associated with bisphosphonate therapies, intersects with individual health outcomes, setting the stage for a more precise discussion of legal and medical implications.

Understanding Fosamax and Its Association with Osteonecrosis of the Jaw

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). While effective at reducing fracture risk, its use has been associated with a rare but serious adverse effect: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves pain, swelling, infection, and delayed healing after dental procedures. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Clinical Evidence

The mechanistic pathways linking Fosamax to ONJ are not fully understood but are believed to involve the drug's potent inhibition of osteoclast-mediated bone resorption. Bisphosphonates like alendronate accumulate in bone, particularly in areas of high turnover such as the jaw. This accumulation can suppress normal bone remodeling, impair blood supply, and reduce the ability of bone to heal after microdamage or dental procedures. Multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research suggests that the unique structure and metabolism of jawbone may make it particularly vulnerable to bisphosphonate-induced suppression of remodeling. The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, ONJ is considered a rare event. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of atypical femoral fracture or osteonecrosis of jaw was uncommon and rare respectively (https://pubmed.ncbi.nlm.nih.gov/42046648/). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Most patients had relief of symptoms after stopping the drug, though a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Adequacy of Warnings and Legal Considerations

Adequacy of warnings regarding Fosamax and ONJ is a key risk consideration. The prescribing information for Fosamax includes a specific warning under section 5.4 titled "Osteonecrosis of the Jaw" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This warning describes the association, risk factors, and clinical management. However, patients and healthcare providers may not be fully aware of the risk, particularly given the rarity of the condition. The label also notes that the optimal duration of use has not been determined, and for patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that long-term use may increase risk, though the evidence on interruption of bisphosphonate prescription for up to two years after either three or five years of prescription was not associated with fragility fracture (https://pubmed.ncbi.nlm.nih.gov/42046648/). For affected patients, attorney-related considerations are important. Individuals who have developed ONJ after taking Fosamax may seek legal counsel to evaluate whether the manufacturer provided adequate warnings about this risk. The prescribing information does include a warning, but the adequacy of that warning in terms of prominence, clarity, and timeliness may be questioned. Patients should be aware that the time to onset of symptoms can vary, and that ONJ is generally associated with dental procedures or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Legal claims may focus on whether the risk was properly communicated to prescribers and patients, and whether alternative treatments or monitoring strategies should have been recommended.

Summary and Next Steps

In summary, Fosamax is an effective bisphosphonate for osteoporosis and other bone conditions, but it carries a rare risk of osteonecrosis of the jaw. The condition is associated with dental procedures and local infection, and the risk may increase with longer duration of use. The prescribing information includes a warning about ONJ, but patients and healthcare providers should remain vigilant. For those affected, consulting with a legal professional may help assess whether the warnings were adequate and whether compensation is warranted.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and what is it used for?

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often presenting with pain, swelling, infection, and delayed healing after dental procedures. It is a rare but serious adverse effect associated with Fosamax use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for ONJ symptoms to appear after starting Fosamax?

The time to onset of symptoms can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Can stopping Fosamax help with ONJ?

Most patients have relief of symptoms after stopping the drug, though a subset may have recurrence if rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

What legal options are available for individuals who developed ONJ after taking Fosamax?

Individuals who have developed ONJ after taking Fosamax may seek legal counsel to evaluate whether the manufacturer provided adequate warnings about this risk. Legal claims may focus on whether the risk was properly communicated to prescribers and patients, and whether alternative treatments or monitoring strategies should have been recommended.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.